Poniard Pharmaceuticals, Inc.
PARD
Rank in Stocks
#35151
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the... Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Share Price
$0.0001
Last synced: 2026-11-13
Market Cap
$149.83
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Poniard Pharmaceuticals, Inc. (PARD)
Category
Healthcare
P/S ratio for Poniard Pharmaceuticals, Inc. (PARD)
P/S ratio as of November 2026 TTM: 0.00
According to Poniard Pharmaceuticals, Inc.'s latest financial reports and stock price, its current price-to-sales ratio (TTM) is 0.00. At the end of 2010 the company had a P/S ratio of 0.00.
P/S ratio history for Poniard Pharmaceuticals, Inc. from 2000 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | -100.00% |
| 2005 | 420.73 | 2,611.56% |
| 2004 | 15.52 | 475.93% |
| 2003 | 2.69 | 937.39% |
| 2002 | 0.26 | -98.04% |
| 2001 | 13.26 | 43.44% |
| 2000 | 9.24 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 18.29 | - |
US
|
|
| 10.51 | - |
US
|
|
| 35.79 | - |
US
|
|
| 4.19 | - |
AU
|
|
| 6.63 | - |
BE
|
Questions about Poniard Pharmaceuticals, Inc.'s P/S ratio
What was Poniard Pharmaceuticals, Inc.'s P/S ratio in 2010?
In 2010, Poniard Pharmaceuticals, Inc.'s P/S ratio was 0.00, compared with 0.00 in 2009.
How has Poniard Pharmaceuticals, Inc.'s P/S ratio changed since 2005?
From 2005 to 2010, Poniard Pharmaceuticals, Inc.'s P/S ratio was highest in 2005 (420.73) and lowest in 2010 (0.00).
How does Poniard Pharmaceuticals, Inc.'s P/S ratio compare with similar companies?
Poniard Pharmaceuticals, Inc.'s P/S ratio (0.00) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 35.79.